Renal cell carcinoma (RCC) is a highly heterogeneous tumour, accounting for 90--95% of total kidney tumours. Clear cell RCC (ccRCC) is the major histological subtype (approximately 80%). Although the RCC incidence rate varies worldwide, it has continued to rise over the past two decades ([@bib3]). Renal cell carcinoma incidence is two-fold higher in men than in women and its prognosis differs by race ([@bib3], [@bib4]; [@bib22]). Surgical resection remains the mainstay of curative treatment. Renal cell carcinoma does not respond to radiotherapy and chemotherapy, but partially responds to targeted therapies or immunotherapy. Although the use of targeted therapies for advanced RCC is promising, there are many challenges for the application of these new approaches ([@bib1]; [@bib7]; [@bib22]). Little progress has been made with regard to the development of specific risk or prognostic biomarkers for RCC.

Compelling epidemiological evidence suggest that occupational exposure to trichloroethylene and pesticide, hypertension, smoking, obesity, urolithiasis, nitrite from animal food, and diabetes are risk factors, whereas green tea intake, cruciferous and dark green vegetables, increased physical activity, the use of statins, alcohol consumption, and occupational ultraviolet exposure are protective factors of ccRCC ([@bib3]; [@bib14]; [@bib36]; [@bib5]). Polymorphisms of xenobiotic metabolism-related genes such as glutathione *S*-transferase mu (GSTM), cytochrome P450 mono-oxygenases, and folate metabolism genes and their interactions with environmental exposure are related to RCC risk ([@bib29]; [@bib12]; [@bib21]; [@bib30]). Recent genome-wide association studies (GWAS) revealed that specific loci mapped on 2p21 (rs11894252), 2q22.3 (rs12105918), 11q13.3 (rs7105934), 12p11.23 (rs718314, rs1049380), and 12q24.31 (rs4765623) were significantly associated with RCC susceptibility ([@bib25]; [@bib27]; [@bib37]; [@bib10]). However, the genetic risk factors found in European population are sometimes unable to be replicated in Asians ([@bib32]). Recent studies have shown that some molecules in tumours, genetic variations, and the neutrophil--lymphocyte ratio predict poor prognosis of RCC ([@bib11]; [@bib13]; [@bib17]; [@bib6]; [@bib15]; [@bib2]; [@bib24]). However, the causal factors for this malignancy in Asians remain obscure.

In our previous study, we identified a group of deregulated genes in ccRCC using cDNA microarray and *GSTM3*, a GSTM-class subunit, was found to be not only downregulated in metastatic ccRCC cells compared with primary ccRCC cells, but also downregulated in primary ccRCC tissues compared the adjacent normal renal tissues ([@bib35]). The role of *GSTM3* in the occurrence and progression of RCC is not clear. Here we report that *GSTM3* can function as a tumour suppressor in RCC and a specific polymorphism predisposing to downregulating *GSTM3* in kidney is significantly associated with the occurrence and postoperative prognosis of RCC.

Materials and methods
=====================

Cell culture, transfection, and knockdown of GSTM3
--------------------------------------------------

NRCC, a ccRCC cell line isolated from a patient without distant metastasis in our laboratory ([@bib34]), and 786-O and ACHN ccRCC cell lines purchased from American Tissue Culture Collection (ATCC) (Manassas, VA, USA) within 2 months before our *in vitro* study were maintained in DMEM or RPMI 1640 (Hyclone, Thermo Fisher Scientific, Pittsburgh, PA, USA) supplemented with 10% fetal calf serum (GIBCO, Invitrogen, Grand Island, NY, USA), 100 U ml^--1^ penicillin, and 100 *μ*g ml^--1^ streptomycin. A full-length of human GSTM3 cDNA clone (MHS4771-99611057) was purchased from Thermo Fisher Scientific (Pittsburgh, PA, USA), released by *Bam*HI and *Xho*I digestion, and inserted into mammalian expression vector pcDNA3.1/V5-His TOPO (Invitrogen, Carlsbad, CA, USA). After identified with direct DNA sequencing, pcDNA3.1/V5-His TOPO-GSTM3 construct was transfected into NRCC cells using lipofectamine 2000 Reagent (Invitrogen, Grand Island, NY, USA). Stable GSTM3-expressing cells were selected in the presence of 1400 *μ*g ml^--1^ G418 (Sigma-Aldrich, St Louis, MO, USA) for 14 days. Transient transfection of pcDNA3.1/V5-His TOPO-GSTM3 construct into 786-O and ACHN cells was performed using FuGENE HD Transfection Reagent (Promega, Madison, WI, USA) and lipofectamine LTX and Plus Reagent (Invitrogen, Grand Island, NY, USA) without antibiotics selection, respectively.

The retrovirus packing vector Pegpam 3e, RDF vector and pSuper-retro vector were kindly provided by Dr Yang ([@bib33]). The sequences of small hairpin RNA (shRNA) targeting to *GSTM3* were 5′-AATCGCTGCCTACTTACAGTC-3′ (shGSTM3-1); 5′-AACAACAAGATGCCCAGTGG-3′ (shGSTM3-2); 5′-CTGGCATCGGTGTGGATGA-3′ (shsiscramble: a pSUPER-vector construct containing a non-gene targeting DNA sequence, served as a negative control). Retroviral supernatants were generated as previously described ([@bib33]). NRCC cells were incubated with virus-containing medium supplemented with 4 *μ*g ml^--1^ polybrene (Sigma-Aldrich). Stable GSTM3-knockdown cells were selected in the presence of 3.5 *μ*g ml^--1^ puromycin (Sigma-Aldrich) for 7 days. Transient transfection of shRNA constructs targeted to GSTM3 was performed in 786-O and ACHN cells without antibiotics selection.

Glutathione *S*-transferase mu 3 expression was examined by quantitative reverse transcription PCR (qRT-PCR) and western blot as previously described ([@bib33]; [@bib34]). The primers for the amplification of GSTM3 cDNA were 5′-TTGGAAGAGCTACCTGGACAA-3′ (forward) and 5′-CCTTCAGGTTTGG GAACTCA-3′ (reverse), for GAPDH (an internal control) were 5′-GACCCCTTCATTGACCTCAAC-3′ (forward) and 5′-CTTCTCCATGGTGGTGAAGA-3′ (reverse).

Anchorage-independent growth, invasion, and cell cycle analysis
---------------------------------------------------------------

Anchorage-independent growth potential was evaluated by double-layered soft agarose culture system. Cell invasion assay was performed using 8-*μ*m pore size 24-well tissue culture Transwell plates (Corning, NY, USA). Cell cycle of NRCC-shsiscramble and NRCC-shGSTM3-1 cells was examined with flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA). These assays were carried out as previously described ([@bib34]). All examinations were performed in triplicate.

Study population
----------------

We enrolled a total of 400 newly diagnosed RCC patients and 802 healthy controls (free of diagnosed cancers of any histotype and other clinical diseases). The RCC patients received curative nephrectomy at Department of Urology in Changhai and Changzheng hospitals affiliated to Second Military Medical University from May 1998 to November 2011. Surgical specimens were pathologically identified by a pathologist (YY). None of the enrolled patients received other treatments before or after surgery. Healthy controls were randomly selected from those who received annual physical examination at Physical Examination Center of Changhai hospital from May 2006 to November 2011. The characteristics of RCC patients and healthy controls in the case--control study are included in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. Cases and controls were matched on gender while healthy controls were older than RCC patients (*P*\<0.001) according to frequency matching. Of the 400 RCC patients, 374 were pathogenically diagnosed as ccRCC and 43 were at advanced stage (AJCC stage III, 26; stage IV, 17). We also acquired freshly frozen tumour tissues and their paired adjacent renal tissues from 13 ccRCC patients who received surgery at Department of Urology in Changhai hospital for comparative analysis of GSTM3 expression. Flow diagram of study subjects enrolled onto a case--control study and postoperative survival analyses is presented in [Figure 1](#fig1){ref-type="fig"}. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, and was approved by the Institutional Ethical Review Board of Second Military Medical University. A written informed consent was obtained from each participant.

Selection of single-nucleotide polymorphism (SNP) and genotyping
----------------------------------------------------------------

We searched International HapMap Project ([www.hapmap.org](http://www.hapmap.org)) for *GSTM3*-related SNPs with the minor allele frequency of\>20% in Chinese Han population. rs1332018 (in the promoter, A-63C) is in a transcription factor-binding site and splicing site, with predicted regulatory potential (<http://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/snpfunc.cgi>). Thus, rs1332018 was predicted as a functional SNP. rs7483 is in the coding region, resulting in an amino acid change V224I. Both SNPs were selected because they were also the representatives of two haplotype blocks as determined using online Haploview 4.2 software (<http://hapmap.ncbi.nlm.nih.gov>).

Peripheral blood samples were collected from the patients just before nephrectomy and healthy controls during physical examination and preserved in freezers. Genomic DNA was extracted as previously described ([@bib36]). rs1332018 and rs7483 were genotyped using fluorescent-probe real-time quantitative PCR in LightCycler480 (Roche, Basel, Switzerland) and PCR-confronting two-pair primers (PCR-CTPP; [@bib8]), respectively. Primers and probes were designed and synthesised by GeneCore BioTechnologies (Shanghai, China). Sequences of the primers for rs1332018 were 5′-GGAGGCAAGGGACGGAGA-3′ (forward) and 5′-TTCCGAGCCTTCGAGGACTAG-3′ (reverse). The primers for rs7483 were 5′-CCACCCTGCCATCCTCAAGT-3′ (forward) and 5′-CCCAAGAGAAACTCAGCTGGACA-3′ (reverse). The probes for rs1332018 were FAM-CGCCCCCTTATGTAGGGTATAAAGCCC-TAMRA and HEX-CGCCCCCTTATGTCGGGTATAAAGC-TAMRA. The sequences of allele-specific primers for rs7483 were 5′-CAGTGGGGCAACAAGCCTA-3′ (forward) and 5′-TGCCTCCTGCTCAGCATAC-3′ (reverse). The PCR reaction for genotyping rs1332018 was 95 °C for 10 s, 40 cycles of 95 °C for 10 s, 60 °C for 30 s, and 40 °C for 1 s; for genotyping rs7483 was 95 °C for 3 min, 40 cycles of 95 °C for 30 s, 58 °C for 30 s, 72 °C for 50 s. Allele-specific PCR products were visualised on a 1.5% agarose gel with ethidium bromide staining. The genotyping was performed with two blank controls in each 96-well format of PCR. More than 15% of samples were randomly selected to repeat, yielding a 100% concordance. The success rates of genotyping for the two SNPs were \>99%.

Western blot
------------

Protein was extracted from RCC cells and freshly frozen adjacent renal tissues of 13 ccRCC patients, quantified, and subjected to western blot with rabbit polyclonal antibodies against GSTM3 (1 : 1000; ProteinTech Group, Chicago, IL, USA) and mouse monoclonal antibody to *β*-actin (1 : 1000; Cell Signal, Danvers, MA, USA) as previously described ([@bib34]). Signal intensity of each band was quantified using Genetools software (version 4.02, Cambridge, UK). Relative expression was calculated as that signal intensity of GSTM3 divided by signal intensity of *β*-actin in each lane. A value of ⩾0.8 was defined as a high expression.

Immunohistochemistry
--------------------

Formalin-fixed paraffin-embedded (FFPE) specimens of tumours and their paired adjacent pathologically normal renal tissues from 72 ccRCC patients were examined immunohistochemically for GSTM3 expression. Polyclonal antibodies against GSTM3 (1 : 100; ProteinTech Group) were used for immunostaining. The sections were processed as previously described ([@bib35]). Immunostains were independently assessed by four researchers (XT, TS, YH, and YY) who were blinded of clinical information. Glutathione *S*-transferase mu 3 expression in glomeruli, proximal convoluted tubule, and distal convoluted tubule plus collecting ducts as three independent sites were separately evaluated in each section. For each visual field, the percentage of positive epithelial and endothelial cells was graded as 0 (0--4%), 1 (5--24%), 2 (25--49%), 3 (50--74%), and 4 (\>75%); the intensity of immunostaining was rated as 0 (negative), 1 (weak), 2 (moderate), and 3 (intense). Values of the intensity and the extent were multiplied as an immunoreactive score. We selected three visual fields in each site and scored each visual field independently. A mean score of the three fields was given to each site. The scores of the three sites were sum up and ranked the total score of each sample by −/+ (score 0--3), ++ (score 3--12), and +++ (score \>12). Disagreements on immunoreactive scores for GSTM3 expression in eight (11.11%) patients among the researchers were resolved by consensus.

Follow-up after curative nephrectomy
------------------------------------

Clinicopathological variables before surgery were documented. All the RCC patients were followed up by phone or face-to-face interview every 6 months according to our standard epidemiologic procedure. We excluded patients who lost contact information and those refused to be enrolled in the survival analysis. Death from RCC relapse was defined as an event. Patients alive at the last follow-up and deaths caused by conditions unrelated to RCC were censored. Time scale of the follow-up was from 3 to 176.4 months after surgery. Median follow-up time was 43.5 months (interquartile range: 18.3--67.3 months). The last follow-up date was 27 January 2013. Disease-specific survival (DSS) was measured in months from surgery to death from RCC relapse or censored.

Statistical analysis
--------------------

Hardy--Weinberg equilibrium (HWE) was examined by using online analytical tools (<http://ihg.gsf.de>). The association of rs1332018 genotypes with GSTM3 expression or with AJCC stage was evaluated by Pearson correlation analysis. For the main effect of SNPs, unconditional logistic regression model was conducted to calculate odds ratios (ORs) and their 95% confidence intervals (95% CIs), adjusting for age and gender, in case--control study. For postoperative survival analysis, DSSs and their 95% CIs were estimated by the Kaplan--Meier method. The log-rank test was used to compare DSS between groups. A test of the proportional hazards, a required assumption of Cox regression, was performed for each covariate and globally using the Breslow method in R (<http://www.r-project.org/>). Multivariate stage-stratified Cox proportional hazards model was applied to estimate the hazard ratios (HRs) with 95% CIs for DSS. Age (continuous variable), gender (male *vs* female), and rs1332018 genotype (AC+CC *vs* AA) as predictor variables and AJCC stage (II+IV *vs* I+II) as a stratification variable were introduced into this model. All statistical tests were two-sided and conducted using Statistical Program for Social Sciences (SPSS 16.0, Chicago, IL, USA) and R. A *P-*value of\<0.05 was considered as statistically significant.

Results
=======

GSTM3 expression inversely related to the aggressiveness of RCC cells
---------------------------------------------------------------------

We initially generated stable GSTM3-knockdown and GSTM3-overexpression NRCC cells. Glutathione *S*-transferase mu 3 expression was significantly decreased in NRCC-shGSTM3-1 or NRCC-shGSTM3-2 cells compared with shsiscramble control cells as examined by western blot and qRT-PCR ([Figure 2A](#fig2){ref-type="fig"}). Notably, knockdown of GSTM3 in NRCC cells enhanced anchorage-independent growth in agarose and invasiveness in Transwell plates as compared with the control cells ([Figure 2C and E](#fig2){ref-type="fig"}). As expected, GSTM3 expression was significantly upregulated in NRCC cells after GSTM3 transfection ([Figure 2B](#fig2){ref-type="fig"}). Ectopic overexpression of GSTM3 significantly reduced anchorage-independent growth and invasive potential of ccRCC cells ([Figure 2D and F](#fig2){ref-type="fig"}). Cytometry analysis indicated that NRCC-shGSTM-1 cells had a higher S phase fraction than did the control cells ([Figure 2G](#fig2){ref-type="fig"}). Transient transfection of shRNA-GSTM3 significantly decreased GSTM3 expression while transient transfection of TOPO-GSTM3 significantly increased GSTM3 expression in 786-O and ACHN cells. Furthermore, downregulation of GSTM3 expression significantly increased the invasive abilities in 786-O and ACHN cells and anchorage-independent growth in ACHN cells ([Figure 3](#fig3){ref-type="fig"}).

Association of SNPs with RCC risk
---------------------------------

rs1332018 and rs7483 were conformed to HWE in healthy controls, with *P*-values of 0.947 and 0.388, respectively. Of the two SNPs, rs1332018 variant genotypes were significantly associated with an increased risk of RCC ([Table 1](#tbl1){ref-type="table"}). Compared with rs1332018 AA genotype, the AC and AC+CC genotypes were significantly associated with increased risks of RCC, with ORs of 1.442 (*P*=0.008) and 1.446 (*P*=0.006) adjusting for age and gender, respectively. Compared with the A allele of rs1332018, the C allele was significantly associated with an increased risk of RCC. As ccRCC patients accounted for 93.5% of the patients enrolled, we also analysed the proportions of rs1332018 genotypes in 374 ccRCC patients and 802 healthy controls. The C allele of rs1332018 was significantly associated with an increased risk of ccRCC, with an adjusted OR of 1.393 (*P*=0.006). rs7483 genotype was not significantly associated with the risk of RCC or ccRCC.

Association of rs1332018 genotypes with GSTM3 expression in kidney
------------------------------------------------------------------

To determine whether rs1332018 genotype was related to the level of GSTM3 expression in kidney, we initially demonstrated GSTM3 expression in freshly frozen adjacent normal renal samples from 13 available ccRCC patients with different rs1332018 genotypes by western blot. We found that GSTM3 expression was higher in five of six samples with the AA genotype and lower in five of seven samples with the CC+AC genotypes ([Figure 4A](#fig4){ref-type="fig"}). We then examined GSTM3 expression in the FFPE specimens of adjacent renal specimens of 72 ccRCC patients using immunohistochemistry. In the patients with rs1332018 AA genotype, GSTM3 staining was mainly positive in the membrane and cytoplasm of vascular endothelial cells of glomeruli and epithelial cells of proximal convoluted tubules and distal convoluted tubules and collecting ducts. Interestingly, GSTM3 was selectively positive in a fragment of distal convoluted tubules or collecting ducts but negative in glomeruli and proximal convoluted tubules in those with rs1332018 CC genotype. In RCC tissues with rs1332018 AA or AC genotype, GSTM3 expression was detected in endothelial cells but not detected in cancer epithelial cells; whereas in RCC tissues with rs1332018 CC genotype, GSTM3 expression was seldom detected in both of endothelial cells and cancer epithelial cells. These data are shown in [Figure 4B](#fig4){ref-type="fig"}. The total immunoreactive scores of GSTM3 expression in adjacent normal renal tissues correlated with rs1332018 AA genotype, in contrast to those with the AC+CC genotypes (Pearson *r*=−0.326, *P*=0.005); however, the scores were not significantly correlated to AJCC stages (Pearson *r*=−0.093, *P*=0.436; [Table 2](#tbl2){ref-type="table"}).

Associations of rs1332018 genotypes and GSTM3 expression in adjacent renal tissues with the survival of RCC patients after surgery
----------------------------------------------------------------------------------------------------------------------------------

In all, 310 of the 400 RCC patients enrolled in the case--control study were successfully followed up after surgery. Ninety patients lost to follow-up. Major reason of the failure to follow-up was contact information lost (88.9%). These patients were mostly from other cities and had only temporary local phone number in their medical record. Of the 310 RCC patients, 32 died of RCC relapse. Kaplan--Meier analysis showed that the RCC patients with rs1332018 AA genotype had a favourable postoperative DSS compared with those with the C allele (AC+CC genotypes; log-rank *P*=0.023, [Figure 5A](#fig5){ref-type="fig"}). Compared with the patients at AJCC stages III+IV, those at the stages I+II had a good prognosis (log-rank *P*\<0.001, [Figure 5B](#fig5){ref-type="fig"}). In the ccRCC patients, rs1332018 AC+CC genotypes and late AJCC stages also significantly predicted an unfavourable prognosis, respectively ([Figure 5C and D](#fig5){ref-type="fig"}). Of the 310 RCC patients, 72 ccRCC patients were analysed for GSTM3 expression by using immunohistochemical analysis of their FFPE specimens. Of the 72 patients, 12 died of ccRCC relapse. Positive GSTM3 expression in adjacent renal tissues (positive *vs* negative) significantly predicted an unfavourable DSS (log-rank *P*=0.037; [Figure 5E](#fig5){ref-type="fig"}), whereas advanced AJCC stages did not significantly predict an unfavourable DSS ([Figure 5F](#fig5){ref-type="fig"}) in the 72 ccRCC patients. Multivariate stage-stratified Cox proportional hazards analysis of the 310 patients demonstrated that rs1332018 AC+CC genotypes independently predict an unfavourable postoperative prognosis of RCC or ccRCC ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

In this study, we found that downregulation of GSTM3 expression by shRNA significantly increased the invasive potential and anchorage-independent growth of the three ccRCC cell lines; whereas ectopic overexpression of GSTM3 in NRCC cells decreased the invasive potential and anchorage-independent growth ([Figure 2D and F](#fig2){ref-type="fig"}). We did not observe the effect of GSTM3 overexpression by transient transfection in 786-O and ACHN cells possibly because the expression background of GSTM3 was high in the two cell lines ([Figure 3M](#fig3){ref-type="fig"}). Cytometry analysis indicated that ccRCC cells tended to proliferate faster when GSTM3 was downregulated ([Figure 2G](#fig2){ref-type="fig"}). These data, together with our previous findings ([@bib35]), suggest that GSTM3 may function as a tumour suppressor in ccRCC. Glutathione *S*-transferase mu 3 has been shown to be downregulated in ovarian cancer by using proteomics analysis ([@bib16]). Epigenetic inactivation (promoter hypermethylation) of GSTM3 has been found in Barrett\'s adenocarcinoma ([@bib23]). A significant reduction of GSTM3 expression has been observed in chemical-induced hepatocarcinogenesis ([@bib26]). These data indicate that GSTM3 expression is downregulated in these cancer types. However, it has been shown that GSTM3 expression correlates with lymph node metastasis and advanced stage of colon cancer and low GSTM3 expression is associated with better survival in patients with bladder cancer ([@bib20]; [@bib19]). Thus, GSTM3 function appears to be context dependent and may vary with different cancer types.

We found that a polymorphism (rs1332018) in the promoter region influenced GSTM3 expression in adjacent pathologically normal renal tissues. rs1332018 AA genotype was correlated to high GSTM3 expression while the variant genotype (CC+AC) were correlated to low GSTM3 expression ([Table 2](#tbl2){ref-type="table"}). This is consistent with the previous observations that the CC genotype of rs1332018 is associated with lower GSTM3 expression in brain tumours, normal breast tissues, lymphoblast cells, and glioma cell lines by means of altering binding of RNA polymerase II ([@bib18]; [@bib38]; [@bib28]). This SNP was shown to be functional in previous studies ([@bib18]). Interestingly, we found that GSTM3 was predominantly expressed in vascular endothelial cells of glomeruli and epithelial cells of proximal convoluted tubules in tissues with rs1332018 AA genotype; whereas GSTM3 was exclusively expressed in a fragment of distal convoluted tubules or collecting ducts in those with rs1332018 CC genotype ([Figure 4](#fig4){ref-type="fig"}). The underlying mechanism for the rs1332018 genotype-specific GSTM3 expression patterns in renal units remains unknown, but we believe that GSTM3 and its functional genetic predisposition have important roles in renal function and diseases. Although there is some evidence supporting the concept that ccRCC might origin from collecting ducts and distal tubules ([@bib31]), it is generally believed that ccRCC originates from proximal tubular epithelial cells. Lack of GSTM3 in proximal tubular epithelial cells with rs1332018 variants may facilitate renal carcinogenesis if exposed to carcinogen and by-products of oxidative stress, as GSTM3 is basically a cytosolic enzyme involved in prostaglandin and leukotriene synthesis and in the metabolism of toxic compounds ([@bib9]).

Our case--control study suggested that the C allele of rs1332018 was significantly associated with an increased risk of RCC ([Table 1](#tbl1){ref-type="table"}). However, this SNP was not found to be a risk locus of RCC in recent GWAS, possibly because of the race of study population, coverage of the probes, and correction of multiple comparisons in GWAS ([@bib25]; [@bib37]; [@bib10]). Importantly, the Bonferroni correction in GWAS does not take into account SNP function. In this regard, a key finding of this study is that the C allele of rs1332018 independently predicted an unfavourable postoperative DSS of RCC ([Table 3](#tbl3){ref-type="table"}), indicating the importance of this functional SNP in RCC. It has been shown that the variant genotype of rs1332018 is significantly associated with increased risks of brain tumour and breast cancer ([@bib38]; [@bib28]). Although the activity of GSTM3 promoter with different rs1332018 genotypes should be examined in the RCC cells, we believe that the C allele of rs1332018 predisposes the host to decreasing GSTM3 expression in kidney. We also demonstrated that negative GSTM3 expression in adjacent renal tissues was significantly associated with an unfavourable DSS ([Figure 5](#fig5){ref-type="fig"}). Silencing of GSTM3 expression in renal tissues might facilitate renal carcinogenesis upon carcinogen exposure and also promote disease relapse and metastasis. These data support that GSTM3 is a putative tumour suppressor in these cancer types including RCC. To our knowledge, this is the first study to report that rs1332018 variant genotype was not only a risk factor and but also a prognostic factor of RCC.

Our study had several limitations. First, 90 of the 400 genotyped RCC patients were lost to follow-up. This limitation might not bias the associations of rs1332018 genotypes with RCC risk and postoperative prognosis because contact information lost was the main reason of the lost to follow-up. However, a selection bias might be introduced, at least theoretically, by this percentage (22.5%) of the patients lost to follow-up. Second, RCC-free patients with diseases that increase RCC risk, such as hypertension, should be also considered as controls in this case--control study. Third, the mechanism by which rs1332018 genotypes regulate GSTM3 expression was not fully examined in this study. The effect of rs1332018 variants on the promoter activity of *GSTM3* in renal cells and the role of GSTM3 expression pattern in renal subunits of the individuals with distinct rs1332018 genotypes on renal function warrant further investigation.

In summary, we demonstrated, for the first time, that GSTM3 may function as a tumour suppressor in RCC. The C allele of rs1332018 predisposes host to downregulating GSTM3 in their renal tissues, especially in the membrane and cytoplasm of vascular endothelial cells of glomeruli and epithelial cells of proximal convoluted tubules. rs1332018 variant genotype was not only a significant genetic risk factor and but also a significant prognostic factor for RCC. These findings will be helpful in the surveillance and prognosis prediction of RCC, as well as in the development of targeted therapy for this malignancy. Our report also points to the need for further studies of regulation of GSTM3 expression in RCC.
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![**Flow diagram of study subjects enrolled onto case--control study and survival analysis.** Number in parentheses referred to the number of ccRCC patients.](bjc2013669f1){#fig1}

![**Anchorage-independent growth and invasive potential of ccRCC cell line NRCC with altered expression of GSTM3 by stable transfection.** (**A**) Knockdown of GSTM3 expression by shRNA. (**B**) Ectopic overexpression of GSTM3 by the transfection. (**C**) Knockdown of GSTM3 increased anchorage-independent growth. (**D**) Ectopic overexpression of GSTM3 decreased anchorage-independent growth. (**E**) Knockdown of GSTM3 increased invasive potential. (**F**) Ectopic overexpression of GSTM3 decreased invasive potential. (**G**) Cell cycle analysis by flow cytometry. \**P*\<0.05.](bjc2013669f2){#fig2}

![**Anchorage-independent growth and invasive potential of ccRCC cell lines 786-O and ACHN with altered expression GSTM3 by transient transfection.** \**P*\<0.05, \*\**P*\<0.01. (**A**--**D**) Expression levels of GSTM3 in ACHN and 786-O cells after transient transfection with shRNA constructs and TOPO-GSTM3 construct, respectively, as detected by qRT-PCR and western blot. (**E**--**H**) Invasive potential ACHN and 786-O cells after the transient transfection, as detected by Transwell assay. (**I**--**J**) Anchorage-independent growth in ACHN cells after transient transfection with shRNA constructs and TOPO-GSTM3 construct, as detected by the double-layered soft agarose culture system. (**K**) Background level of GSTM3 expression in ACHN, 786-O and NRCC cells, as detected by western blot.](bjc2013669f3){#fig3}

![**The level and pattern of GSTM3 expression in freshly frozen adjacent renal tissues and formalin-fixed paraffin-embedded specimens of ccRCC patients with different rs1332018 genotypes.** (**A**) Expression level of GSTM3 protein in freshly frozen adjacent renal tissues examined by western blot. (**B**) The immunostaining pattern of GSTM3 expression in glomeruli and proximal convoluted tubules (I, IV, and VII), distal convoluted tubules and collecting ducts (II, V, and VIII) of adjacent renal tissues and the paired RCC tissues (III, VI, and IX) from three patients with rs1332018 genotype of AA, AC, and CC, respectively.](bjc2013669f4){#fig4}

![**Kaplan--Meier analysis of DSS of RCC patients with different rs1332018 genotypes or with different GSTM3 expression levels in adjacent renal tissues.** (**A**) RCC patients with rs1332018 AA genotype *vs* those with the variant (AC+CC) genotype. (**B**) RCC patients at AJCC stages I+II *vs* those at AJCC stages III+IV. (**C**) ccRCC patients with rs1332018 AA genotype *vs* those with the variant (AC+CC) genotype. (**D**) ccRCC patients at AJCC stages I+II *vs* those at AJCC stages III+IV. (**E**) Positive GSTM3 expression *vs* negative GSTM3 expression in the adjacent renal tissues of the 72 ccRCC patients. (**F**) AJCC stages I+II *vs* those at AJCC stages III+IV of the 72 ccRCC patients.](bjc2013669f5){#fig5}

###### The associations of GSTM3 polymorphisms with the risk of RCC and ccRCC

  **Genotype**    **RCC patients (%)**   **ccRCC cases (%)**   **Controls (%)**   **Adjusted OR (95% CI)** [a](#t1-fn2){ref-type="fn"}   ***P*****-value**[a](#t1-fn2){ref-type="fn"}   **Adjusted OR (95% CI)** [b](#t1-fn3){ref-type="fn"}   ***P*****-value**[b](#t1-fn3){ref-type="fn"}
  --------------- ---------------------- --------------------- ------------------ ------------------------------------------------------ ---------------------------------------------- ------------------------------------------------------ ----------------------------------------------
  **rs1332018**                                                                                                                                                                                                                                
  AA              265 (66.3)             246 (65.8)            596 (74.0)         1.000 (Reference)                                      ---                                            ---                                                    ---
  AC              125 (31.2)             118 (31.5)            191 (23.8)         1.442 (1.100--1.890)                                   0.008                                          1.463 (1.111--1.928)                                   0.007
  CC              10 (2.5)               10 (2.7)              15 ( 1.9)          1.524 (0.670--3.466)                                   0.315                                          1.639 (0.721--3.726)                                   0.238
  AC+CC           135 (33.7)             128 (34.2)            206 (25.7)         1.446 (1.111--1.882)                                   0.006                                          1.473 (1.126--1.926)                                   0.005
  A allele        655 (81.9)             610 (81.6)            1383 (86.2)        1.000 (Reference)                                      ---                                            ---                                                    ---
  C allele        145 (18.1)             138 (18.4)            221 (13.8)         1.365 (1.083--1.721)                                   0.008                                          1.393 (1.101--1.762)                                   0.006
  **rs7483**                                                                                                                                                                                                                                   
  AA              224 (56.0)             206 (55.1)            452 (56.4)         1.000 (Reference)                                      ---                                                                                                    
  GA              149 (37.3)             142 (38.0)            294 (36.7)         1.040 (0.804--1.345)                                   0.766                                          1.071 (0.824--1.393)                                   0.608
  GG              27 (6.7)               26 (6.9)              56 ( 7.0)          0.950 (0.582--1.552)                                   0.837                                          0.993 (0.604--1.633)                                   0.978
  GA+GG           176 (44.0)             168 (44.9)            350 (43.6)         1.024 (0.801--1.307)                                   0.852                                          1.057 (0.823--1.356)                                   0.665
  A allele        597 (85.1)             554 (74.1)            1198 (74.7)        1.000 (Reference)                                      ---                                            ---                                                    ---
  G allele        203 (14.9)             194 (25.9)            406 (25.3)         1.004 (0.824--1.222)                                   0.970                                          1.030 (0.843--1.259)                                   0.772

Abbreviations: CI=confidence interval; ccRCC=clear cell renal cell carcinoma; GSTM3=glutathione *S*-transferase mu 3; OR=odds ratio; RCC=renal cell carcinoma.

RCC patients *vs* healthy controls.

ccRCC patients *vs* healthy controls.

###### The association of rs1332018 genotypes and AJCC stage with GSTM3 expression in the adjacent normal renal tissues of 72 ccRCC patients

                    **Total immunoreactive scores of GSTM3 (no.)**                    
  ---------------- ------------------------------------------------ ---- ---- ------- --------
  **rs1332018**                                                                       
  AA                                      13                         14   22  0.005   −0.326
  AC+CC                                   10                         11   2            
  **AJCC stage**                                                                      
  I                                       13                         16   17  0.436   −0.093
  II                                      4                          2    1            
  III                                     3                          7    4            
  IV                                      3                          0    2            

Abbreviations: AJCC=American Joint Committee on Cancer; ccRCC=clear cell renal cell carcinoma; GSTM3=glutathione *S*-transferase mu 3.

###### Factors significantly predicted disease-specific survival in multivariate stage-stratified Cox proportional hazards model

  **Variables**                        **HR (95% CI)** [a](#t3-fn1){ref-type="fn"}   ***P*****-value**[a](#t3-fn1){ref-type="fn"}   **HR (95% CI)** [b](#t3-fn2){ref-type="fn"}   ***P*****-value** [b](#t3-fn2){ref-type="fn"}
  ------------------------------------ --------------------------------------------- ---------------------------------------------- --------------------------------------------- -----------------------------------------------
  Age                                  1.005 (0.978, 1.033)                          0.720                                          1.005 (0.977, 1.034)                          0.740
  Gender (male *vs* female)            1.102 (0.532, 2.283)                          0.790                                          1.127 (0.538, 2.362)                          0.750
  rs1332018 genotype (AC+CC *vs* AA)   2.119 (1.043, 4.307)                          0.038                                          2.248 (1.091, 4.631)                          0.028

Abbreviations: CI=confidence interval; ccRCC=clear cell renal cell carcinoma; HR=hazard ratio; RCC=renal cell carcinoma.

For RCC.

For ccRCC.

[^1]: These authors contributed equally to this work.
